Tonix Pharmaceuticals (TNXP)

Search documents
Tonix Pharmaceuticals Holding (TNXP) Presents At Biotech Showcase 2020 - Slideshow
2020-01-14 15:58
Investor Presentation Biotech Showcase 2020 Version P0217 1-13-20 (Doc 0584) © 2020 Tonix Pharmaceuticals Holding Corp. 1 Cautionary Note on Forward-Looking Statements 2 Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast ...
Tonix Pharmaceuticals Holding (TNXP) Investor Presentation - Slideshow
2019-12-05 20:30
Investor Presentation December 2019 Version P0208 12-3-19 (Doc 0565) © 2019 Tonix Pharmaceuticals Holding Corp. 1 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estima ...
Tonix Pharmaceuticals (TNXP) - 2019 Q3 - Quarterly Report
2019-11-08 21:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) (State ...
Tonix Pharmaceuticals Holding (TNXP) Investor Presentation - Slideshow
2019-10-29 10:51
Investor Presentation October 2019 Version P0200 10-16-19 (Doc 0543) © 2019 Tonix Pharmaceuticals Holding Corp. 1 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estima ...
Tonix Pharmaceuticals (TNXP) Investor Presentation - Slideshow
2019-09-17 20:01
Investor Presentation September 2019 Version P0195 9-13-19 (Doc 0531) © 2019 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimat ...
Tonix Pharmaceuticals (TNXP) - 2019 Q2 - Quarterly Report
2019-08-12 11:51
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 26-1 ...
Tonix Pharmaceuticals (TNXP) - 2019 Q1 - Quarterly Report
2019-05-13 11:51
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d ...
Tonix Pharmaceuticals (TNXP) Investor Presentation - Slideshow
2019-03-29 21:03
Investor Presentation March 2019 Version P0167 3-18-19 (Doc 0451) © 2019 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" a ...
Tonix Pharmaceuticals (TNXP) - 2018 Q4 - Annual Report
2019-03-18 11:50
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Exact name of registrant as specified in its charter) Nevada 26-1434750 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 509 Madison Avenue, Suite 1608 New York, New York 10022 (212) 980-9155 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDI ...
Tonix Pharmaceuticals Holding (TNXP) Investor Presentation - Slideshow
2019-02-11 18:23
Investor Presentation February 2019 Version P0158 2-5-19 (Doc 0435) © 2019 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward-Looking Statements 2 Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimat ...